|
ZNF260 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.06279999642933E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.77579999996558E-06 |
| Normal-vs-Stage2 |
1.155040E-03 |
| Normal-vs-Stage3 |
5.00790000024232E-07 |
| Normal-vs-Stage4 |
6.1396000505809E-09 |
| Stage1-vs-Stage2 |
7.674200E-01 |
| Stage1-vs-Stage3 |
1.263990E-01 |
| Stage1-vs-Stage4 |
8.753300E-04 |
| Stage2-vs-Stage3 |
1.867420E-01 |
| Stage2-vs-Stage4 |
5.358900E-03 |
| Stage3-vs-Stage4 |
9.305700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.10460000041424E-07 |
| Normal-vs-AfricanAmerican |
4.902800E-03 |
| Normal-vs-Asian |
1.62663999999646E-05 |
| Caucasian-vs-AfricanAmerican |
9.476200E-01 |
| Caucasian-vs-Asian |
4.896400E-01 |
| AfricanAmerican-vs-Asian |
6.420600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.71281999999939E-05 |
| Normal-vs-Female |
4.80970000493741E-08 |
| Male-vs-Female |
6.334000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.83726999999356E-05 |
| Normal-vs-Age(41-60Yrs) |
1.39860000025749E-07 |
| Normal-vs-Age(61-80Yrs) |
3.2505000002736E-07 |
| Normal-vs-Age(81-100Yrs) |
3.758800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.335400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.624400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.751200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.341200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.148200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.045000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.585900E-02 |
| Classical-VS-Follicular |
1.582200E-01 |
| Classical-VS-Other |
7.884200E-01 |
| Classical-VS-Normal |
3.66439999999191E-06 |
| Tall-VS-Follicular |
2.305400E-01 |
| Tall-VS-Other |
6.533400E-01 |
| Tall-VS-Normal |
1.12819999997793E-06 |
| Follicular-VS-Other |
9.619600E-01 |
| Follicular-VS-Normal |
3.58000000000303E-06 |
| Other-VS-Normal |
7.117900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.64189999996012E-06 |
| Normal-vs-N1 |
5.39389999998363E-07 |
| N0-vs-N1 |
1.073580E-01 |
|
|
